AC
AIGH Capital Management LLC
13F filer · CIK 0001835943Reported Aug 7, 2026
Net buyer this quarter
13F portfolio value$1.59BU.S. long equity reported on 13F
Positions4216 new · 14 closed
Net flow last quarter+$141MBuys minus sells
Top 10 positions weight51.4%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 7, 202642 positions | |||||
| $339M | 21.35% | 0.10% | -25.5% | Q3 2025 | |
| $105M | 6.60% | 0.90% | Not reported | Q3 2025 | |
| $87.1M | 5.49% | 0.01% | New | Q2 2026 | |
| $84.5M | 5.32% | 5.41% | +33.8% | Q1 2023 | |
| $48M | 3.03% | 0.11% | -28.0% | Q3 2021 | |
| $40.1M | 2.53% | 7.42% | New | Q2 2026 | |
| $31.8M | 2.01% | 4.73% | New | Q2 2026 | |
| $28.9M | 1.82% | 7.15% | Not reported | Q3 2021 | |
| $26.7M | 1.68% | 7.10% | +25.5% | Q1 2023 | |
| $24.9M | 1.57% | 4.54% | +39.8% | Q4 2025 | |
| $24.6M | 1.55% | 33.78% | New | Q2 2026 | |
| $23M | 1.45% | 1.61% | -40.9% | Q3 2024 | |
| $22.8M | 1.44% | 5.77% | New | Q2 2026 | |
| $22M | 1.38% | 4.95% | New | Q2 2026 | |
| $19.6M | 1.23% | 7.99% | +104.7% | Q4 2020 | |
| $18.5M | 1.16% | 5.22% | -3.7% | Q4 2021 | |
| $16.3M | 1.03% | 1.28% | Not reported | Q4 2021 | |
| $15.3M | 0.96% | 6.43% | -10.6% | Q4 2022 | |
| $13.5M | 0.85% | 9.08% | Not reported | Q1 2023 | |
| $13M | 0.82% | 1.79% | -7.7% | Q3 2025 | |
| $12.5M | 0.79% | 3.38% | -25.7% | Q4 2020 | |
| $9.3M | 0.59% | 8.85% | New | Q2 2026 | |
| $7.64M | 0.48% | 8.27% | -5.6% | Q1 2024 | |
| $7.36M | 0.46% | 2.13% | -3.7% | Q4 2024 | |
| $5.58M | 0.35% | 4.94% | Not reported | Q1 2023 | |
| $5.55M | 0.35% | 8.29% | New | Q2 2026 | |
| $5.16M | 0.33% | 1.05% | New | Q2 2026 | |
| $5.07M | 0.32% | 2.68% | +2.1% | Q1 2023 | |
| $4.8M | 0.30% | 5.45% | -24.3% | Q4 2020 | |
| $4.74M | 0.30% | 8.87% | -1.3% | Q3 2025 | |
| $4.64M | 0.29% | 2.59% | -72.7% | Q1 2026 | |
| $4.38M | 0.28% | 3.29% | -15.4% | Q1 2026 | |
| $4.32M | 0.27% | 9.76% | +18.9% | Q1 2025 | |
| $3.81M | 0.24% | 1.86% | New | Q2 2026 | |
| $3.8M | 0.24% | 4.17% | +30.0% | Q1 2025 | |
| $3.7M | 0.23% | 2.69% | -35.2% | Q4 2022 | |
| $3.65M | 0.23% | 6.02% | +254.2% | Q1 2026 | |
| $2.64M | 0.17% | 415.56% | -25.0% | Q3 2023 | |
| $815K | 0.05% | 8.20% | Not reported | Q1 2023 | |
| $700K | 0.04% | 5.21% | -19.2% | Q1 2024 | |
| $339K | 0.02% | 0.10% | +37.3% | Q4 2025 | |
| $41.3K | 0.00% | 0.02% | New | Q2 2026 | |
| Q1 2026Reported Apr 30, 202640 positions | |||||
| $127M | 17.33% | 0.14% | -28.6% | Q3 2025 | |
| $27.4M | 3.73% | 9.60% | New | Q1 2026 | |
| $22.5M | 3.06% | 0.15% | Not reported | Q3 2021 | |
| $20.9M | 2.85% | 0.20% | New | Q1 2026 | |
| $19.4M | 2.64% | 0.60% | -43.3% | Q2 2025 | |
| $19M | 2.59% | 4.57% | +37.6% | Q4 2020 | |
| $18.5M | 2.52% | 2.77% | Not reported | Q3 2024 | |
| $17.6M | 2.40% | 0.15% | New | Q1 2026 | |
| $17.3M | 2.35% | 3.30% | +33.3% | Q4 2025 | |
| $14.5M | 1.98% | 1.95% | -5.5% | Q3 2025 | |
| $14.1M | 1.92% | 4.07% | Not reported | Q1 2023 | |
| $14M | 1.92% | 0.11% | New | Q1 2026 | |
| $13.9M | 1.89% | 5.45% | +55.0% | Q4 2021 | |
| $13.5M | 1.84% | 2.89% | +50.0% | Q3 2025 | |
| $12.2M | 1.66% | 5.74% | +25.3% | Q1 2023 | |
| ETESPREsperion Therapeutics, Inc. | $12.1M | 1.64% | 1.71% | +10.0% | Q3 2025 |
| $11.2M | 1.53% | 2.03% | Not reported | Q2 2024 | |
| $11M | 1.50% | 7.50% | Not reported | Q4 2022 | |
| $10.6M | 1.45% | 7.50% | +25.0% | Q1 2024 | |
| $10.6M | 1.45% | 2.28% | Not reported | Q4 2024 | |
| $8.45M | 1.15% | 2.95% | New | Q1 2026 | |
| $7.61M | 1.04% | 3.96% | Not reported | Q4 2020 | |
| $6.98M | 0.95% | 8.75% | +18.7% | Q1 2024 | |
| $4.08M | 0.56% | 2.64% | Not reported | Q1 2023 | |
| $3.84M | 0.52% | 4.16% | Not reported | Q4 2022 | |
| $3.78M | 0.51% | 554.24% | +17.2% | Q3 2023 | |
| $3.68M | 0.50% | 8.23% | +30.8% | Q1 2025 | |
| $3.48M | 0.47% | 9.31% | Not reported | Q3 2025 | |
| $3.37M | 0.46% | 3.91% | New | Q1 2026 | |
| $3.34M | 0.46% | 9.76% | +140.2% | Q4 2020 | |
| $2.96M | 0.40% | 3.49% | Not reported | Q1 2025 | |
| $2.43M | 0.33% | 0.87% | -84.6% | Q2 2021 | |
| $1.6M | 0.22% | 2.68% | New | Q1 2026 | |
| $1.51M | 0.21% | 1.71% | New | Q1 2026 | |
| $1M | 0.14% | 0.16% | -90.3% | Q4 2020 | |
| $917K | 0.12% | 5.79% | New | Q1 2026 | |
| $775K | 0.11% | 8.48% | +174.1% | Q1 2023 | |
| $740K | 0.10% | 7.71% | Not reported | Q1 2024 | |
| $337K | 0.05% | 0.07% | +3.4% | Q4 2025 | |
| $204K | 0.03% | 4.22% | +32.7% | Q2 2024 | |
| Q4 2025Reported Feb 2, 202631 positions | |||||
| $66.5M | 16.09% | 0.19% | Not reported | Q3 2025 | |
| $24.3M | 5.88% | 2.10% | -11.7% | Q3 2025 | |
| $23.1M | 5.59% | 2.83% | -25.5% | Q3 2024 | |
| $22.5M | 5.45% | 1.17% | Not reported | Q2 2025 | |
| DODAWNDay One Biopharmaceuticals, Inc. | $18.6M | 4.49% | 1.93% | +31.0% | Q3 2025 |
| $17.6M | 4.27% | 3.38% | Not reported | Q4 2020 | |
| $15.8M | 3.82% | 5.66% | +113.6% | Q2 2021 | |
| DDOMODomo, Inc. | $15.5M | 3.75% | Not reported | +37.0% | Q1 2025 |
| ETESPREsperion Therapeutics, Inc. | $14.8M | 3.58% | 1.67% | +33.3% | Q3 2025 |
| $14.1M | 3.41% | 2.48% | New | Q4 2025 | |
| $12.2M | 2.95% | 4.63% | +132.1% | Q1 2023 | |
| $11.1M | 2.69% | 1.89% | +14.5% | Q4 2020 | |
| $10.5M | 2.55% | 3.63% | Not reported | Q4 2021 | |
| $8.11M | 1.96% | 6.00% | Not reported | Q1 2024 | |
| $7.62M | 1.84% | 2.41% | +100.0% | Q3 2025 | |
| $7.43M | 1.80% | 5.32% | -11.9% | Q2 2024 | |
| $6.7M | 1.62% | 0.47% | +479.4% | Q4 2021 | |
| $6.63M | 1.60% | 1.74% | New | Q4 2025 | |
| $5.83M | 1.41% | 7.38% | +26.1% | Q1 2024 | |
| $5.66M | 1.37% | 4.66% | -11.8% | Q4 2022 | |
| $5.31M | 1.29% | 9.45% | +4.7% | Q3 2025 | |
| $3.87M | 0.94% | 2.64% | Not reported | Q1 2023 | |
| $3.67M | 0.89% | 7.74% | +8.4% | Q1 2025 | |
| $3.15M | 0.76% | 5.86% | Not reported | Q4 2024 | |
| $2.13M | 0.51% | 472.99% | -3.1% | Q3 2023 | |
| $1.82M | 0.44% | 3.75% | Not reported | Q1 2025 | |
| $1.52M | 0.37% | 5.76% | -4.1% | Q4 2020 | |
| $719K | 0.17% | 9.87% | +58.7% | Q2 2024 | |
| $712K | 0.17% | 0.09% | New | Q4 2025 | |
| $522K | 0.13% | 7.86% | -12.5% | Q1 2024 | |
| $316K | 0.08% | 4.52% | -31.3% | Q1 2023 | |
| Q3 2025Reported Oct 31, 202534 positions | |||||
| $31.4M | 8.85% | 0.19% | New | Q3 2025 | |
| $25.4M | 7.15% | 4.39% | +4.5% | Q3 2024 | |
| DDOMODomo, Inc. | $21.2M | 5.99% | Not reported | Not reported | Q1 2025 |
| $18.5M | 5.20% | 6.04% | -2.8% | Q2 2024 | |
| $17.8M | 5.02% | 1.27% | New | Q3 2025 | |
| $17.8M | 5.01% | 1.18% | Not reported | Q2 2025 | |
| $16.1M | 4.54% | 2.43% | New | Q3 2025 | |
| $15.6M | 4.40% | 0.25% | New | Q3 2025 | |
| $11.7M | 3.30% | 2.19% | +34.1% | Q2 2024 | |
| DODAWNDay One Biopharmaceuticals, Inc. | $10.7M | 3.02% | 1.48% | New | Q3 2025 |
| $9.75M | 2.75% | 1.36% | Not reported | Q1 2023 | |
| $8.36M | 2.36% | 2.65% | Not reported | Q2 2021 | |
| $8.01M | 2.26% | 2.04% | -41.0% | Q1 2025 | |
| ETESPREsperion Therapeutics, Inc. | $7.95M | 2.24% | 1.49% | New | Q3 2025 |
| $7.14M | 2.01% | 2.10% | -75.3% | Q4 2020 | |
| $6.38M | 1.80% | 2.43% | +50.6% | Q1 2023 | |
| $6.3M | 1.78% | 6.60% | Not reported | Q4 2022 | |
| $5.28M | 1.49% | 8.22% | New | Q3 2025 | |
| $5.05M | 1.42% | 0.60% | New | Q3 2025 | |
| $4.13M | 1.16% | 0.12% | New | Q3 2025 | |
| $3.98M | 1.12% | 9.77% | New | Q3 2025 | |
| $3.55M | 1.00% | 6.80% | -10.8% | Q1 2024 | |
| $3.32M | 0.94% | 7.14% | -24.6% | Q1 2025 | |
| $3.23M | 0.91% | 1.17% | New | Q3 2025 | |
| $2.82M | 0.79% | 487.93% | -8.3% | Q3 2023 | |
| $2.81M | 0.79% | 1.13% | Not reported | Q4 2020 | |
| $2.7M | 0.76% | 6.42% | -19.6% | Q4 2024 | |
| $2.58M | 0.73% | 6.03% | -23.3% | Q4 2020 | |
| $1.23M | 0.35% | 4.05% | Not reported | Q1 2025 | |
| $1.13M | 0.32% | 0.46% | -91.1% | Q3 2023 | |
| $1.09M | 0.31% | 0.08% | Not reported | Q4 2021 | |
| $1.03M | 0.29% | 8.98% | +7.3% | Q1 2024 | |
| $795K | 0.22% | 9.02% | Not reported | Q1 2023 | |
| $714K | 0.20% | 7.59% | -3.1% | Q2 2024 | |
Premium opens every quarter this fund has filed